Effect of dapagliflozin in patients with heart failure

Commentary and context are provided for an RCT which found dapagliflozin reduced hospitalisation for heart failure or cardiovascular death vs placebo. The benefits appeared to be lower in those with NYHA class III and IV heart failure and in patients taking sacubitril/valsartan.

SPS commentary:

NICE TA679 recommends dapagliflozin for symptomatic chronic heart failure with reduced ejection fraction only if it is used as an add-on to optimised standard care with:

  • angiotensin-converting enzyme (ACE) inhibitors or angiotensin‑2 receptor blockers (ARBs), with beta blockers, and, if tolerated, mineralocorticoid receptor antagonists (MRAs), or
  • sacubitril valsartan, with beta blockers, and, if tolerated, MRAs.

 

Drug and Therapeutics Bulletin

Resource links:

NICE TA679